In 2018, regulators pulled valsartan tablets off shelves worldwide after finding trace amounts of a chemical called NDMA inside the active ingredient. Ranitidine and metformin followed a similar path over the next two years. The common thread was a class of compounds known as nitrosamines, and the fallout changed how the entire industry looks at impurity control.
Nitrosamine impurities are chemical byproducts that can form during drug manufacturing, storage, or even packaging. The International Agency for Research on Cancer classifies several of them as probable human carcinogens. What makes them so troublesome isn’t potency in the traditional sense — it’s that regulators expect them to be controlled at parts-per-billion levels, far below what most quality labs were built to measure a decade ago.
Where Nitrosamine Impurities Come From
The basic chemistry is not complicated. A secondary or tertiary amine reacts with a nitrite source under acidic or otherwise favorable conditions, and a nitrosamine forms. The hard part is that this reaction can be triggered by almost anything in a manufacturing environment that contains nitrogen and comes into contact with the wrong reagent.
A few common sources show up again and again in regulatory findings.
- Synthesis routes themselves are the biggest offender. Solvents like DMF, or amine-based reagents and catalysts, can introduce the exact building blocks needed for nitrosamine formation, especially when a nitrosating agent is present somewhere in the process, even in trace form.
- Shared production equipment is another factor. Recovered or recycled solvents that were not fully purged of amine residues can carry contamination from one batch to another, even across different products.
- Raw materials and water quality matter more than people usually assume. Starting materials with amine impurities, or process water treated with chloramine, can supply the nitrite needed to complete the reaction.
- Packaging can play a role too. Certain blister films and container materials degrade under heat or light and release compounds that act as nitrosating agents, contaminating the drug product after it has already left the manufacturing site.
FDA and EMA Rules on Nitrosamines
Both agencies now require sponsors to treat nitrosamine control as an ongoing obligation, not a one-time test. The acceptable intake limits for common nitrosamines such as NDMA and NDEA are set in nanograms per day, which is an extremely small threshold compared to typical impurity limits.
The expected approach generally follows three stages.
- Step one is a risk assessment. Manufacturers review the synthetic route, raw materials, and manufacturing conditions to judge whether nitrosamine formation is plausible at any stage.
- Step two is confirmatory testing. If the risk assessment flags a concern, the product needs to be tested with methods sensitive enough to detect nanogram-level contamination.
- Step three covers mitigation and reporting. If testing confirms a risk, the manufacturer adjusts the process, retests, and files the required changes with regulators, often as part of a drug master file update.
Agencies have made clear that silence is not an acceptable answer. A file with no documented risk assessment is treated as incomplete, regardless of how the product has performed historically.
Testing and Detecting N-Nitrosamines
Standard HPLC methods, the workhorse of most quality labs, simply do not have the sensitivity these limits demand. Detecting a few nanograms of contaminant against a background of active ingredient requires a different level of instrumentation.
LC-MS/MS and GC-MS/MS are now the standard tools for this work. Both combine chromatographic separation with mass spectrometry, which gives labs the specificity to distinguish a nitrosamine from other trace compounds and the sensitivity to catch it at the parts-per-billion level. Method development for these assays takes real expertise, since each nitrosamine species behaves a little differently depending on the drug matrix it sits in.
Choosing an API Supplier That Controls Nitrosamine Risk
For a pharmaceutical company, the practical risk isn’t abstract. Sourcing an active ingredient from a supplier without a documented nitrosamine control program can mean a recall years after launch, once a regulator or an internal audit turns up contamination that should have been caught at the design stage. Recalls of this kind cost far more than the price difference between a cheap API and a well-controlled one.
Regulatory filings now expect a nitrosamine risk assessment as a standard part of the drug master file package, not an afterthought added after an inspection finding.
At Arbor Pharmchem, this gets built into the process from day one rather than added later. Every starting material goes through a documented sourcing review before it enters a synthesis route. Reaction pathways are chosen specifically to avoid combining amine-containing reagents with nitrosating agents in the same step. Our QC lab runs LC-MS/MS testing in-house, and we provide full nitrosamine risk assessment reports alongside our intermediates and custom synthesis projects, so customers can drop that documentation directly into their own regulatory submissions. This ensures that even complex processes, like those used to achieve high enantiomeric excess, meet the strictest safety standards.
Frequently Asked Questions
Why are nitrosamine impurities dangerous?
They are classified as probable human carcinogens, and long-term exposure even at low doses is linked to increased cancer risk. That’s why regulators set limits in nanograms per day rather than the milligram or microgram ranges used for most other impurities.
What are the most common nitrosamines found in drugs?
NDMA and NDEA show up most frequently in regulatory findings, though NMBA, NDIPA, and several others have also been identified depending on the drug class and synthesis route involved.
Can nitrosamine formation be avoided entirely?
In most cases, yes. Careful route selection, vetted raw materials, and process controls that keep amines and nitrosating agents apart can keep nitrosamine levels well below the acceptable intake limits, often to the point of being undetectable.
Need an API or intermediate backed by a complete nitrosamine risk assessment? Contact Arbor Pharmchem for our compliance documentation and product catalog.
